BDNF and Tau as biomarkers of severity in multiple sclerosis
Determine if serum levels of tau and BDNF can be used as severity biomarkers in multiple sclerosis (MS). Subjects with MS, older than 18 and younger than 55 years old were included; 74 patients with a diagnosis of relapsing-remitting MS, 11 with secondary-progressive MS, and 88 controls were include...
Gespeichert in:
| Veröffentlicht in: | Biomarkers in medicine 2018-07, Vol.12 (7), p.717-726 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 726 |
|---|---|
| container_issue | 7 |
| container_start_page | 717 |
| container_title | Biomarkers in medicine |
| container_volume | 12 |
| creator | Islas-Hernandez, Azul Aguilar-Talamantes, Hugo Seacatl Bertado-Cortes, Brenda Mejia-delCastillo, Georgina de Jesus Carrera-Pineda, Raul Cuevas-Garcia, Carlos Fredy Garcia-delaTorre, Paola |
| description | Determine if serum levels of tau and BDNF can be used as severity biomarkers in multiple sclerosis (MS).
Subjects with MS, older than 18 and younger than 55 years old were included; 74 patients with a diagnosis of relapsing-remitting MS, 11 with secondary-progressive MS, and 88 controls were included. Total tau and BDNF were measured by Western blot.
Increased tau and decreased BDNF in MS patients compared with controls was found. Total-tau has a peak in relapsing-remitting MS, the second decile of the multiple sclerosis severity score, and in the lowest expanded disability status scale and is no different than controls for secondary-progressive MS patients and the most severe cases of MS.
BDNF is a good biomarker for diagnosis of MS but not for severity or progression. Tau appears to have a more active role in the progression of MS. |
| doi_str_mv | 10.2217/bmm-2017-0374 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2050483959</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2216510826</sourcerecordid><originalsourceid>FETCH-LOGICAL-c410t-593bf8c6177f9a9a7c9ee68dcac7a245ea96fc1456a28b81e340847c13458c3b3</originalsourceid><addsrcrecordid>eNp1kE1LAzEQhoMotlaPXiXgxctqks3XghetVoWil3oO2XQWUvejJrtC_70prR4ET5nAM-_MPAidU3LNGFU3ZdNkjFCVkVzxAzSmSrBtTQ9_a5mP0EmMK0KEUpIdoxErtBRa8DG6vX94nWHbLvHCDthGXPquseEDQsRdhSN8QfD9BvsWN0Pd-3UNOLoaQhd9PEVHla0jnO3fCXqfPS6mz9n87ellejfPHKekz0SRl5V2kipVFbawyhUAUi-ddcoyLsAWsnKUC2mZLjWFnBPNlaM5F9rlZT5BV7vcdeg-B4i9aXx0UNe2hW6IhhFBuM6LNGiCLv-gq24IbdrOJF1SUKKZTFS2o1y6IwaozDr4dPbGULLllElazVar2WpN_MU-dSgbWP7SPx4TUOyAauiHANF5aB2Y3S91eOdb-Cf8G4NHhJM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2216510826</pqid></control><display><type>article</type><title>BDNF and Tau as biomarkers of severity in multiple sclerosis</title><source>PubMed Central</source><creator>Islas-Hernandez, Azul ; Aguilar-Talamantes, Hugo Seacatl ; Bertado-Cortes, Brenda ; Mejia-delCastillo, Georgina de Jesus ; Carrera-Pineda, Raul ; Cuevas-Garcia, Carlos Fredy ; Garcia-delaTorre, Paola</creator><creatorcontrib>Islas-Hernandez, Azul ; Aguilar-Talamantes, Hugo Seacatl ; Bertado-Cortes, Brenda ; Mejia-delCastillo, Georgina de Jesus ; Carrera-Pineda, Raul ; Cuevas-Garcia, Carlos Fredy ; Garcia-delaTorre, Paola</creatorcontrib><description>Determine if serum levels of tau and BDNF can be used as severity biomarkers in multiple sclerosis (MS).
Subjects with MS, older than 18 and younger than 55 years old were included; 74 patients with a diagnosis of relapsing-remitting MS, 11 with secondary-progressive MS, and 88 controls were included. Total tau and BDNF were measured by Western blot.
Increased tau and decreased BDNF in MS patients compared with controls was found. Total-tau has a peak in relapsing-remitting MS, the second decile of the multiple sclerosis severity score, and in the lowest expanded disability status scale and is no different than controls for secondary-progressive MS patients and the most severe cases of MS.
BDNF is a good biomarker for diagnosis of MS but not for severity or progression. Tau appears to have a more active role in the progression of MS.</description><identifier>ISSN: 1752-0363</identifier><identifier>EISSN: 1752-0371</identifier><identifier>DOI: 10.2217/bmm-2017-0374</identifier><identifier>PMID: 29865854</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>binary logistic regression ; biomarker ; Biomarkers ; Brain-derived neurotrophic factor ; Consent ; Diagnosis ; expanded disability status scale ; Fluids ; Multiple sclerosis ; multiple sclerosis severity score ; Patients ; progression ; Proteins ; Serum levels ; Systematic review ; tau ; Western blot</subject><ispartof>Biomarkers in medicine, 2018-07, Vol.12 (7), p.717-726</ispartof><rights>2018 Future Medicine Ltd</rights><rights>Copyright Future Medicine Ltd Jul 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c410t-593bf8c6177f9a9a7c9ee68dcac7a245ea96fc1456a28b81e340847c13458c3b3</citedby><cites>FETCH-LOGICAL-c410t-593bf8c6177f9a9a7c9ee68dcac7a245ea96fc1456a28b81e340847c13458c3b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29865854$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Islas-Hernandez, Azul</creatorcontrib><creatorcontrib>Aguilar-Talamantes, Hugo Seacatl</creatorcontrib><creatorcontrib>Bertado-Cortes, Brenda</creatorcontrib><creatorcontrib>Mejia-delCastillo, Georgina de Jesus</creatorcontrib><creatorcontrib>Carrera-Pineda, Raul</creatorcontrib><creatorcontrib>Cuevas-Garcia, Carlos Fredy</creatorcontrib><creatorcontrib>Garcia-delaTorre, Paola</creatorcontrib><title>BDNF and Tau as biomarkers of severity in multiple sclerosis</title><title>Biomarkers in medicine</title><addtitle>Biomark Med</addtitle><description>Determine if serum levels of tau and BDNF can be used as severity biomarkers in multiple sclerosis (MS).
Subjects with MS, older than 18 and younger than 55 years old were included; 74 patients with a diagnosis of relapsing-remitting MS, 11 with secondary-progressive MS, and 88 controls were included. Total tau and BDNF were measured by Western blot.
Increased tau and decreased BDNF in MS patients compared with controls was found. Total-tau has a peak in relapsing-remitting MS, the second decile of the multiple sclerosis severity score, and in the lowest expanded disability status scale and is no different than controls for secondary-progressive MS patients and the most severe cases of MS.
BDNF is a good biomarker for diagnosis of MS but not for severity or progression. Tau appears to have a more active role in the progression of MS.</description><subject>binary logistic regression</subject><subject>biomarker</subject><subject>Biomarkers</subject><subject>Brain-derived neurotrophic factor</subject><subject>Consent</subject><subject>Diagnosis</subject><subject>expanded disability status scale</subject><subject>Fluids</subject><subject>Multiple sclerosis</subject><subject>multiple sclerosis severity score</subject><subject>Patients</subject><subject>progression</subject><subject>Proteins</subject><subject>Serum levels</subject><subject>Systematic review</subject><subject>tau</subject><subject>Western blot</subject><issn>1752-0363</issn><issn>1752-0371</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kE1LAzEQhoMotlaPXiXgxctqks3XghetVoWil3oO2XQWUvejJrtC_70prR4ET5nAM-_MPAidU3LNGFU3ZdNkjFCVkVzxAzSmSrBtTQ9_a5mP0EmMK0KEUpIdoxErtBRa8DG6vX94nWHbLvHCDthGXPquseEDQsRdhSN8QfD9BvsWN0Pd-3UNOLoaQhd9PEVHla0jnO3fCXqfPS6mz9n87ellejfPHKekz0SRl5V2kipVFbawyhUAUi-ddcoyLsAWsnKUC2mZLjWFnBPNlaM5F9rlZT5BV7vcdeg-B4i9aXx0UNe2hW6IhhFBuM6LNGiCLv-gq24IbdrOJF1SUKKZTFS2o1y6IwaozDr4dPbGULLllElazVar2WpN_MU-dSgbWP7SPx4TUOyAauiHANF5aB2Y3S91eOdb-Cf8G4NHhJM</recordid><startdate>20180701</startdate><enddate>20180701</enddate><creator>Islas-Hernandez, Azul</creator><creator>Aguilar-Talamantes, Hugo Seacatl</creator><creator>Bertado-Cortes, Brenda</creator><creator>Mejia-delCastillo, Georgina de Jesus</creator><creator>Carrera-Pineda, Raul</creator><creator>Cuevas-Garcia, Carlos Fredy</creator><creator>Garcia-delaTorre, Paola</creator><general>Future Medicine Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20180701</creationdate><title>BDNF and Tau as biomarkers of severity in multiple sclerosis</title><author>Islas-Hernandez, Azul ; Aguilar-Talamantes, Hugo Seacatl ; Bertado-Cortes, Brenda ; Mejia-delCastillo, Georgina de Jesus ; Carrera-Pineda, Raul ; Cuevas-Garcia, Carlos Fredy ; Garcia-delaTorre, Paola</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c410t-593bf8c6177f9a9a7c9ee68dcac7a245ea96fc1456a28b81e340847c13458c3b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>binary logistic regression</topic><topic>biomarker</topic><topic>Biomarkers</topic><topic>Brain-derived neurotrophic factor</topic><topic>Consent</topic><topic>Diagnosis</topic><topic>expanded disability status scale</topic><topic>Fluids</topic><topic>Multiple sclerosis</topic><topic>multiple sclerosis severity score</topic><topic>Patients</topic><topic>progression</topic><topic>Proteins</topic><topic>Serum levels</topic><topic>Systematic review</topic><topic>tau</topic><topic>Western blot</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Islas-Hernandez, Azul</creatorcontrib><creatorcontrib>Aguilar-Talamantes, Hugo Seacatl</creatorcontrib><creatorcontrib>Bertado-Cortes, Brenda</creatorcontrib><creatorcontrib>Mejia-delCastillo, Georgina de Jesus</creatorcontrib><creatorcontrib>Carrera-Pineda, Raul</creatorcontrib><creatorcontrib>Cuevas-Garcia, Carlos Fredy</creatorcontrib><creatorcontrib>Garcia-delaTorre, Paola</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Biomarkers in medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Islas-Hernandez, Azul</au><au>Aguilar-Talamantes, Hugo Seacatl</au><au>Bertado-Cortes, Brenda</au><au>Mejia-delCastillo, Georgina de Jesus</au><au>Carrera-Pineda, Raul</au><au>Cuevas-Garcia, Carlos Fredy</au><au>Garcia-delaTorre, Paola</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>BDNF and Tau as biomarkers of severity in multiple sclerosis</atitle><jtitle>Biomarkers in medicine</jtitle><addtitle>Biomark Med</addtitle><date>2018-07-01</date><risdate>2018</risdate><volume>12</volume><issue>7</issue><spage>717</spage><epage>726</epage><pages>717-726</pages><issn>1752-0363</issn><eissn>1752-0371</eissn><abstract>Determine if serum levels of tau and BDNF can be used as severity biomarkers in multiple sclerosis (MS).
Subjects with MS, older than 18 and younger than 55 years old were included; 74 patients with a diagnosis of relapsing-remitting MS, 11 with secondary-progressive MS, and 88 controls were included. Total tau and BDNF were measured by Western blot.
Increased tau and decreased BDNF in MS patients compared with controls was found. Total-tau has a peak in relapsing-remitting MS, the second decile of the multiple sclerosis severity score, and in the lowest expanded disability status scale and is no different than controls for secondary-progressive MS patients and the most severe cases of MS.
BDNF is a good biomarker for diagnosis of MS but not for severity or progression. Tau appears to have a more active role in the progression of MS.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>29865854</pmid><doi>10.2217/bmm-2017-0374</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1752-0363 |
| ispartof | Biomarkers in medicine, 2018-07, Vol.12 (7), p.717-726 |
| issn | 1752-0363 1752-0371 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2050483959 |
| source | PubMed Central |
| subjects | binary logistic regression biomarker Biomarkers Brain-derived neurotrophic factor Consent Diagnosis expanded disability status scale Fluids Multiple sclerosis multiple sclerosis severity score Patients progression Proteins Serum levels Systematic review tau Western blot |
| title | BDNF and Tau as biomarkers of severity in multiple sclerosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T10%3A29%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=BDNF%20and%20Tau%20as%20biomarkers%20of%20severity%20in%20multiple%20sclerosis&rft.jtitle=Biomarkers%20in%20medicine&rft.au=Islas-Hernandez,%20Azul&rft.date=2018-07-01&rft.volume=12&rft.issue=7&rft.spage=717&rft.epage=726&rft.pages=717-726&rft.issn=1752-0363&rft.eissn=1752-0371&rft_id=info:doi/10.2217/bmm-2017-0374&rft_dat=%3Cproquest_cross%3E2216510826%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2216510826&rft_id=info:pmid/29865854&rfr_iscdi=true |